❌💊 Simvastatin + rifaximin does not prevent ACLF development in decompensated cirrhosis
⏳10 years of work in the books
💪🏼 @salvatore_piano @Zac_MD @KGananandan @UschnerFrank @JonelTrebicka @ruben_hernaez @JuanAbraldes @JordiGratacos8 @dewitkoos @EASLnews @AASLDtweets
⏳10 years of work in the books
💪🏼 @salvatore_piano @Zac_MD @KGananandan @UschnerFrank @JonelTrebicka @ruben_hernaez @JuanAbraldes @JordiGratacos8 @dewitkoos @EASLnews @AASLDtweets
In this clinical trial, addition of simvastatin plus rifaximin to standard therapy did not improve outcomes in patients with decompensated liver cirrhosis.
ja.ma/3CGXxqBView quoted post on X
